Arvinas Begins Clinical Trial for Immuno-Oncology Candidate ARV-6723

NEW HAVEN, Conn., Sept. 28, 2026 /CourierPR/ -- Arvinas, a clinical-stage biotechnology company, has announced the first patient has been dosed in a Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. This trial, known as ARV-6723-101 (NCT07749586), is a global, multicenter effort aimed at assessing the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ARV-6723 as a monotherapy or in combination with pembrolizumab in adults with advanced solid tumors.

HPK1 acts as a negative regulator of immune activation and is expressed across multiple cell types, including T cells, B cells, natural killer cells, and dendritic cells. ARV-6723 is designed to degrade and remove the HPK1 protein and its signaling scaffolding, potentially addressing both its kinase-dependent and kinase-independent functions. Preclinical studies have shown that ARV-6723 can degrade HPK1 and enhance immune activity, demonstrating meaningful single-agent activity in seven preclinical models where neither an HPK1 inhibitor nor anti-PD-1 therapy showed benefit.

The clinical trial will initially evaluate the safety of ARV-6723 as a monotherapy treatment and subsequently in combination with an anti-PD-1 therapy. The initial monotherapy cohort of this trial is enrolling patients who have received a prior immune checkpoint inhibitor and have no suitable standard treatment options. The goal is to determine whether deep and sustained HPK1 degradation translates into meaningful antitumor effects in patients.

Arvinas, Inc. (Nasdaq: ARVN) is dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas has advanced multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-806, targeting KRAS G12D for solid tumors.

The advancement of ARV-6723 into the clinic represents an important step in expanding the application of targeted protein degradation into immuno-oncology. Resistance to immunotherapy remains a significant challenge, and traditional combinations targeting other immune pathways have not provided a reliable way to prevent or reverse it. The encouraging preclinical data for ARV-6723, including activity in models resistant to immune checkpoint inhibitors, support clinical investigation of its potential to address this unmet need for patients.

Arvinas is headquartered in New Haven, Connecticut, and continues to progress its clinical-stage biotechnology programs. The company’s Annual Report on Form 10-K for the year ended December 31, 2025, provides additional insights into its financial and operational performance.